Why Healthcare?

Hey guys,

I know I'm going to get heat for this, but why would someone choose to go into healthcare investment banking? I know it's one of those industries that will continue, but the volatility and unpredictability seems to be a deterrent.

Any info will help.

11 Comments
 
Best Response
  • Active M&A environment centered around cost-managing and pricing leverage (merging hospital systems, PBM, biotech/pharma, insurance, e.g. Shire-Baxalta, Pfizer-Allergan, Aetna-Humana, Anthem-Cigna, UNH-Catamaran, the list goes on...)
  • Cost savings and operating efficiencies from consolidation of EMR/EHR platforms and emergent info tech
  • New and life-altering treatments are being developed for previously-economically-unfeasible drugs for rare diseases (Shire-Baxalta)
  • "Panacea" drugs with much greater effectiveness and safety profile for patients (adalimumab, sofosbuvir, etc)
  • Further fundamental changes in value model of drug development (Allergan, Valeant, etc)
  • Leveraging population health implementation brings challenges, promises huge value (Optum/UNH, etc)
  • Breeding ground for new technology and new models for Incentivizing human behavior to improve care and generate value (e.g. servicing noncompliant patient populations)

Massive industry disruptions are generally a good thing for investment bankers.

 
"Solidarity"

- Active M&A environment centered around cost-managing and pricing leverage (merging hospital systems, PBM, biotech/pharma, insurance, e.g. Shire-Baxalta, Pfizer-Allergan, Aetna-Humana, Anthem-Cigna, UNH-Catamaran, the list goes on...)
- Cost savings and operating efficiencies from consolidation of EMR/EHR platforms and emergent info tech
- New and life-altering treatments are being developed for previously-economically-unfeasible drugs for rare diseases (Shire-Baxalta)
- "Panacea" drugs with much greater effectiveness and safety profile for patients (adalimumab, sofosbuvir, etc)
- Further fundamental changes in value model of drug development (Allergan, Valeant, etc)
- Leveraging population health implementation brings challenges, promises huge value (Optum/UNH, etc)
- Breeding ground for new technology and new models for Incentivizing human behavior to improve care and generate value (e.g. servicing noncompliant patient populations)

Massive industry disruptions are generally a good thing for investment bankers.

wow sir, this is most useful. we should have such a post for every coverage group.
 
"Solidarity"

- Active M&A environment centered around cost-managing and pricing leverage (merging hospital systems, PBM, biotech/pharma, insurance, e.g. Shire-Baxalta, Pfizer-Allergan, Aetna-Humana, Anthem-Cigna, UNH-Catamaran, the list goes on...)
- Cost savings and operating efficiencies from consolidation of EMR/EHR platforms and emergent info tech
- New and life-altering treatments are being developed for previously-economically-unfeasible drugs for rare diseases (Shire-Baxalta)
- "Panacea" drugs with much greater effectiveness and safety profile for patients (adalimumab, sofosbuvir, etc)
- Further fundamental changes in value model of drug development (Allergan, Valeant, etc)
- Leveraging population health implementation brings challenges, promises huge value (Optum/UNH, etc)
- Breeding ground for new technology and new models for Incentivizing human behavior to improve care and generate value (e.g. servicing noncompliant patient populations)

Massive industry disruptions are generally a good thing for investment bankers.

I assume the Insurance mergers will fall under FIG and not Healthcare?

 

It's usually both healthcare and insurance. Source: work in HC IB

I am a blogging intern at Wall Street Oasis. Feel free to follow me to see my weekly posts.
 
"DiamondsDancing"Professor told me that healthcare will never be fixed; therefore, you will always be guaranteed a job there

Sadly, there's some truth to this.

 

not a banker, but we have a lot of clients in healthcare. a couple reasons make this an attractive industry:

  1. plenty of venture money interested in it, so early companies with interesting compounds/delivery methods will have capital available to them, so that takes care of early stage

  2. FDA is becoming very friendly to innovative drugs that cure a lot of diseases, like immunotherapies

  3. mature companies that own the molecules have cash to make acquisitions

  4. marketers generate tons of free cash flow to make acquisitions once the drugs become marketable

  5. pharma got really fat over the past 2 decades, but it has recently gotten leaner, with companies getting more focused, spinning off divisions, etc. this goes in waves, expect that cycle to continue.

 

Itaque minima eveniet sed nostrum. Velit sit in quos qui explicabo ut.

Quae quo quo eveniet dolores expedita tenetur dolores. Aut voluptate repellat iure cupiditate expedita. Voluptas praesentium vitae est autem enim provident nulla. Quod cupiditate fugit qui quisquam. Tempora nostrum voluptates a accusamus.

Consequatur quia error harum recusandae. Autem molestiae ab perspiciatis. Nihil necessitatibus facilis molestiae sit. Ducimus perspiciatis et ea quos eligendi in provident. Error quod sed quis ea in.

Ut quo ut modi cupiditate aut ducimus accusantium aut. Neque velit tempora impedit laborum. Illum blanditiis ipsam quibusdam ea. Ipsum sint voluptatem omnis doloribus.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (48) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (83) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”